Abstract：Objective To study the clinical effect of Levosimendan in the treatment of refractory heart failure. Methods A total of 98 patients with refractory heart failure admitted to our hospital from September 2017 to June 2018 were randomly selected as the study subjects. They were divided into the reference group and the experimental group according to the randomized comprehensive balance method, with 49 cases in each group. Patients in the reference group were treated with Dobutamine Hydrochloride, and patients in the experimental group were treated with Levosimendan. The therapeutic effect of the two groups were observed, including the total effective rate of treatment and the occurrence of adverse reactions during the treatment. The cardiac index, heart rate index, cardiac output, left ventricular end diastolic diameter, left ventricular ejection fraction were recorded after treatment. The electron luminescence detection kit was used to measure the level of blood N-terminal B-type natriuretic peptide of the two groups. Results The total effective rate of treatment in the experimental group was 93.88%, which was significantly higher than that in the reference group(67.35%), and the difference was statistically significant (P＜0.05). The total incidence rate of adverse reactions in the experimental group was 8.16% (4/49), which was significantly lower than that in the reference group accounting for 30.61% (15/49), and the difference was statistically significant (P＜0.05). The cardiac index, heart rate index, cardiac output and left ventricular ejection fraction of the experimental group were significantly higher than those of the reference group, the left ventricular end-diastolic diameter was lower than that of the reference group, and the differences were statistically significant (P＜0.05). The level of blood N-terminal B-type natriuretic peptide in the experimental group was (1275.54±421.16) ng/L, which was lower than that in the reference group of (1852.44±425.43) ng/L, and the difference was statistically significant (P＜0.05). Conclusion Levosimendan has a significant effect in the treatment of refractory heart failure, and it can accurately improve the various indicators of the heart, and reduce the negative impact of adverse reactions, which is worthy of clinical application and promotion.
京公网安备 11010502046607号